Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Bob Asmussen is a college football reporter and columnist for The News-Gazette. He can be reached at 217-393-8248 or asmussen ...

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

A federal grand jury returned an indictment on May 20, charging two Peoria men, Titus Alexander, 32, and Mitchell Smith, 43, ...

Indiana State’s baseball team clinched its Missouri Valley Conference tournament bid with a convincing 17-3 victory over Illinois State in seven innings Friday afternoon at Bob Warn Field.

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

A man in Marengo, Illinois, is on a mission to fully restore a World War II-era B-17 bomber—a project he’s been diligently ...

Illinois 17/91 over the Spoon River west of Wyoming; lane reductions continue with traffic controlled by temporary signals. Feather Road and Armington Road over I-155; closed. Anyone traveling ...

Researchers from Protagonist Therapeutics Inc. reported the preclinical characterization of PN-881, an oral macrocyclic peptide that inhibits the dimeric forms of IL-17 – AA, AF, and FF. IL-17 plays a ...